In many diseases, the first and most challenging step is identifying the cause—think of cancer, dementia, or Parkinson’s—before researchers can focus on finding a cure. ALD, however, is unique. We already know the exact cause: a malfunctioning ABCD1 gene. This critical knowledge allows researchers to direct their efforts toward repairing this gene or slowing the disease's progression.

One of the most promising breakthroughs is gene therapy. Scientists have developed innovative methods to target and repair the ABCD1 gene, and ALD was one of the first diseases to benefit from an FDA-approved gene therapy. This milestone demonstrates the tangible progress being made in treating ALD and provides a foundation for further advancements.

Another reason for hope is timing. ALD typically doesn’t begin affecting children until around age three, giving families and researchers a crucial window to intervene. As the patient population grows, there is an opportunity to make investments now that could change outcomes for children worldwide.

However, a significant challenge remains: because ALD is classified as “rare,” it doesn’t receive the same level of federal or philanthropic funding as more common diseases. Researchers urgently need financial resources to develop better models and run simultaneous trials that accelerate progress. Our mission is to close this gap by directing donations toward targeted initiatives we believe will have the greatest impact.